Search

everythinglearnresearchcommunity

for

Search:↓

A woman's masculine features were caused by a rare ovarian tumor that produced male hormones.

Benign ovarian tumors can cause excess male hormones and related conditions in postmenopausal women.

A woman with a rare hormone resistance condition also had missing teeth and hair loss, which might be new symptoms of her genetic disorder.

Hair loss in postmenopausal women due to ovarian hyperthecosis is rare, but removing the ovaries can significantly improve the condition.

A 71-year-old woman developed male-like features due to high testosterone levels caused by a benign ovarian tumor, which was successfully removed by surgery.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

The research found that MRI and certain hormone levels can help tell apart ovarian tumors from hyperthecosis in postmenopausal women, but tissue analysis is still needed for a definite diagnosis.

Some ovarian tumors can cause masculinization, and it's important to check for various causes when this symptom is present.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

A woman's high testosterone levels and related symptoms improved after ovary removal surgery.

The document concludes that early diagnosis and treatment are crucial for managing skin diseases in ferrets.

High levels of ST14 and TMEFF1 proteins in ovarian cancer are linked to worse patient outcomes and may be a new treatment target.

ATP-sensitive K+ channel subunits, particularly Sur2A, play a significant role in various cancers.

The document concludes that accurate diagnosis of male and female gonadal disorders is crucial for effective treatment and better patient outcomes.

Chemotherapy in the first trimester of pregnancy is risky, but in the second and third trimesters, it's generally safe with careful drug selection and timing.

The document concludes that fexofenadine reduces inflammation in chronic hives, cholestyramine helps half of pregnant women with itchy rashes, and relaxing incisions are a good alternative in facial surgery for the elderly.

The document concluded that more research is needed to understand how estrogen affects the enzyme involved in hirsutism development.

A woman's pelvic pain and bleeding led to finding and successfully treating a rare benign tumor in her reproductive system.

The Li-Pa/Ca and Do/Ca chemotherapy regimens for serous ovarian cancer showed better short-term and long-term results than the Pa/Ca regimen.

Minoxidil can stop the growth of ovarian cancer cells without harming the heart.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

CD99 is highly present in certain skin cells and could help treat skin conditions.

Some breast cancer treatments, like taxanes, can cause long-term hair loss.

Certain hair straighteners and dyes may increase ovarian cancer risk, especially in African American/Black women.

The meeting showcased rare skin disease cases, highlighting the need for accurate diagnosis and treatment.

A woman's small ovarian tumor causing high androgen levels was missed by several scans but found during surgery.

Older ovarian cancer patients live longer and tolerate weekly chemotherapy better than three-weekly treatments.